



> **THE PATIENT**
22-year-old woman

- > **SIGNS & SYMPTOMS**
- Daily headaches
 - Associated nausea
 - Obesity

Aarti Paltoo, MD, MSc,
CCFP; Anne Picciano, MD
JFK Medical Center, Edison,
NJ

paltooa@mcmaster.ca

The authors reported no potential conflict of interest relevant to this article.

> THE CASE

A 22-year-old woman presented to our office complaining of headaches that started 6 weeks earlier. Initially the headache was throbbing, nonpositional, infrequent, and intermittent, lasting 15 to 45 minutes, often starting in the neck and migrating towards the right fronto-temporal region. During the week prior to presentation, the headaches became daily and constant, with brief periods of relief after the patient took ibuprofen 400 mg 4 times a day as needed. The patient reported associated nausea, a sensation of pressure changes in the ears, and intermittent dimming of vision in the right eye (sometimes independent of headache). The patient denied photophobia and phonophobia. Her only medication was an oral contraceptive pill (OCP). She had no prior history of headaches.

Physical examination showed a blood pressure of 148/66 mm Hg, body mass index of 44.38, muscle tenderness in the neck and upper back, and no focal neurological findings. Funduscopic examination was unsuccessful. A working diagnosis of atypical migraine was made, but because of unilateral visual disturbance the patient was referred to Ophthalmology for further evaluation. The following day, ophthalmological consultation found bilateral papilledema and the patient was admitted to our hospitalist service via the Emergency Department. She subsequently was referred to inpatient Neurology.

THE DIAGNOSIS

Magnetic resonance imaging (MRI) of the brain and orbits with and without contrast was unremarkable. Magnetic resonance venography (MRV) with contrast of the brain showed possible stenosis at the junction of the transverse and sigmoid sinuses but no mass lesion nor venous sinus thrombosis. Lumbar puncture (LP) revealed an opening pressure of 650 mm H₂O (reference range, 60–250 mm H₂O).¹ A diagnosis of idiopathic intracranial hypertension (IIH) was made.

DISCUSSION

IIH, previously known as pseudotumor cerebri and benign intracranial hypertension, is defined by signs and symptoms of elevated intracranial pressure (ICP) without obvious cause on neuroimaging (TABLE 1²⁻⁵). It is well documented that IIH is consequential and can result in vision loss and intractable chronic headaches.^{5,6} Older terms such as pseudotumor cerebri and benign intracranial hypertension are therefore no longer recommended because they are considered misleading and not reflective of the severity of potential injury caused by the condition.^{3,4,6} IIH is considered a diagnosis of exclusion requiring certain criteria to be met (TABLE 2²). Although the etiology of IIH is unclear, associations have been made between IIH and various medications and conditions^{2-5,7} (TABLE 3^{3,5}).

■ **Classically**, IIH affects women who are obese and of childbearing age, but studies have shown that this condition also can affect men and children—albeit less frequently.^{3,5-7} The incidence of IIH in the general population is between 0.03 to 2.36/100,000 people per year, but in women, the incidence is 0.65 to 4.65/100,000 per year.⁶ Furthermore, females who are obese have an incidence of 2.7 to 19.3/100,000 per year.⁶

Headache is the most common symptom of IIH. Unfortunately, the differential diagnosis of headache is vast; thus, a careful history is needed to narrow the field^{3,5-7} (TABLE 4²). Associated symptoms of transient visual changes, pulsatile tinnitus, neck and back pain, nausea, vomiting, photo/phonophobia, and findings of abducens nerve palsy or papilledema—while nonspecific—should raise suspicion for elevated ICP and IIH, especially in women who are obese.²⁻⁸ Once IIH is suspected, an urgent diagnosis and treatment is necessary to prevent permanent vision loss.^{3,4,6}

Headache with findings of papilledema warrants neuroimaging, preferably with MRI, to rule out intracranial mass and hydrocephalus.^{1,2,5} MRV also is recommended to assess for intracranial venous thrombosis, an alternate cause for papilledema and increased ICP.^{1,2,4,5}

Recently, a classification of IIH without papilledema has been acknowledged by the International Headache Society.^{2,8} Specific MRI findings have been suggested to help make this diagnosis^{5,9} (TABLE 5⁵).

TREATMENT FOR IIH CAN BE MEDICAL OR SURGICAL

Medications associated with IIH should be discontinued.⁷ The first-line medication for IIH is acetazolamide, a carbonic anhydrase inhibitor that works in the choroid plexus to decrease cerebrospinal fluid (CSF) production and thus, lower ICP.^{3,6} An adult dose of 1 to 2 g/day^{3,4,6} is tolerated well, but can be increased to 4 g/day,¹⁰ if necessary. Weight loss via diet and exercise or bariatric surgery has been shown to be effective in patients who are

TABLE 1

Secondary causes for increased intracranial pressure²⁻⁵

| |
|--|
| Arachnoid granulation adhesions post meningial infection |
| Choroid plexus papilloma |
| Jugular vein compression |
| Mass lesion (tumor, abscess) |
| Neck surgery |
| Obstructive hydrocephalus |
| Subarachnoid hemorrhage |
| Venous sinus thrombosis |

TABLE 2

International Headache Society classification of headache attributed to IIH diagnostic criteria²

| |
|---|
| A. Progressive headache with ≥ 1 of the following characteristics fulfilling criteria C and D (below): |
| 1. daily occurrence |
| 2. diffuse and/or constant (nonpulsating) pain |
| 3. aggravated by coughing or straining |
| B. Intracranial hypertension fulfilling the following criteria: |
| 1. Alert patient with neurological examination that either is normal or has ≥ 1 of the following abnormalities: |
| a. papilledema |
| b. enlarged blind spot |
| c. visual field defect |
| d. sixth nerve palsy |
| 2. Increased CSF pressure > 250 mm H ₂ O measured by lumbar puncture in the recumbent position or by epidural or intraventricular pressure monitoring |
| 3. Normal CSF chemistry and cellularity |
| 4. Intracranial diseases (including venous sinus thrombosis) ruled out by appropriate investigations |
| 5. No metabolic, toxic, or hormonal cause of intracranial hypertension |
| C. Headache develops in close temporal relation to increased intracranial pressure |
| D. Headache improves after withdrawal of CSF to reduce pressure to 120–170 mm H ₂ O* and resolves within 72 hours of persistent normalization of intracranial pressure |

IIH, idiopathic intracranial hypertension; CSF, cerebrospinal fluid.

*Reference range, 60–250 mm H₂O.

obese and have been given a diagnosis of IIH.^{3,4}

Topiramate also has been suggested as a treatment option, based on its usefulness

TABLE 3

Medications and conditions associated with idiopathic intracranial headache^{3,5}

| Medications | Conditions |
|--|---------------------------|
| Antibiotics (tetracyclines and derivatives, nalidixic acids, nitrofurantoin) | Anemia |
| Cimetidine | Addison disease |
| Corticosteroids | Cushing disease |
| Cyclosporine | Chronic renal failure |
| Danazol | Hypoparathyroidism |
| Human growth hormone | Hypo- and hyperthyroidism |
| Levothyroxine | Obstructive sleep apnea |
| Lithium | |
| Oral contraceptives | |
| Vitamin A excess and retinoids | |

TABLE 4

Differential for chronic headache²

| |
|--|
| Cluster headache |
| Epileptic seizures |
| Hypoxia/hypercapnea (obstructive sleep apnea, high altitude, diving) |
| Infection (meningitis, sinusitis) |
| Metabolic disorders |
| Migraine |
| Neoplasm |
| Neuralgia (occipital, trigeminal) |
| Obstructive sleep apnea |
| Post-trauma (traumatic brain injury) |
| Psychiatric disorder (somatization, panic disorder, PTSD) |
| Structural malformations (Arnold-Chiari malformation) |
| Substance induced, overuse or withdrawal related (nitric oxide, phosphodiesterase inhibitors, NSAIDs, cocaine, caffeine, alcohol, opiates) |
| Tension headache |
| Vascular (arterial aneurysm, temporal arteritis, hypertensive urgency, cerebral vascular accident) |

NSAIDs, nonsteroidal anti-inflammatory drugs; PTSD, post-traumatic stress disorder.

in weight loss and because of its action as a weak carbonic anhydrase inhibitor.^{3,6} Also, LP has therapeutic merit—although relief is only short-term.^{3,6} Patients who fail medical therapy and have intractable headache or progressive visual loss appear to benefit from optic nerve sheath fenestration.^{3,7,8}

■ **Our patient** experienced notable im-

provement in her headache after LP. Her OCP was discontinued, a diuretic regimen started, and weight loss counseling was provided. Prior to discharge, the patient was seen by a neuro-ophthalmologist for perimetry, a visual field test that assesses for acute vision loss and establishes a baseline for follow-up monitoring of vision.⁷

TABLE 5

Revised diagnostic criteria for idiopathic intracranial hypertension⁵

| IIH (Typical) | |
|---|--|
| A. Papilledema | |
| B. Normal neurologic examination +/- cranial nerve abnormalities | |
| C. Neuroimaging: Normal brain parenchyma void of hydrocephalus, meningeal abnormalities, lesions as seen on MRI +/- gadolinium and MRV to also rule out venous sinus thrombosis | |
| D. Normal CSF composition | |
| E. Elevated LP opening pressure > 250 mm H ₂ O (adults); > 280 mm H ₂ O (children); > 250 mm H ₂ O if not sedated or obese (children) | |
| IIH without papilledema qualifies if criteria B-E are met and the patient also has unilateral or bilateral abducens nerve palsy; or in the absence of papilledema and abducens nerve palsy, an IIH diagnosis can be suggested if criteria B-E are met and 3 of the following neuroimaging criteria are satisfied: | |
| 1. Empty sella turcica | |
| 2. Flattening of the posterior aspect of the globe | |
| 3. Distension of the perioptic subarachnoid space +/- tortuous optic nerve | |
| 4. Transverse venous sinus stenosis | |

CSF, cerebrospinal fluid; IIH, idiopathic intracranial hypertension; LP, lumbar puncture; MRI, magnetic resonance imaging; MRV, magnetic resonance venography.

THE TAKEAWAY

Headache is a common condition that may be challenging to correctly diagnose. A thorough history and neurological examination, including funduscopy, are essential in the evaluation of headache and suspected IIH. In the primary care setting, limited time, lack of mydriatic agents, suboptimal lighting, and practitioner inexperience may pose challenges for fundoscopic examination. Ophthalmoscopes incorporating new technology to expand and magnify the examiner's field of view may facilitate this exam.¹¹ A global rise in the prevalence of obesity underscores a need for primary care providers to be compulsive about their clinical evaluation when symptoms suspicious of IIH are present. Lastly, if IIH cannot be ruled out confidently, recommend a prompt evaluation by an ophthalmologist.

JFP

CORRESPONDENCE

Aarti Paltoo, MD, MSc, CCFP, Peel Village Medical Center, 28 Rambler Drive, Brampton, Ontario L6W 1E2 Canada; paltooa@mcmaster.ca

References

1. Lee SC, Lueck CJ. Cerebrospinal fluid pressure in adults. *J Neuroophthalmol*. 2014;34:278-283.
2. International Headache Society. Idiopathic intracranial hypertension. *The International Classification of Headache Disorders*. 2nd ed. Oxford, UK: Blackwell Publishing; 2003:1-232.
3. Biouesse V, Bruce BB, Newman NJ. Update on the pathophysiology and management of idiopathic intracranial hypertension. *J Neurol Neurosurg Psychiatry*. 2012;83:488-494.
4. Mollan SP, Markey KA, Benzimra JD, et al. A practical approach to diagnosis, assessment and management of idiopathic intracranial hypertension. *Pract Neurol*. 2014;14:380-390.
5. Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. *Neurology*. 2013;81:1159-1165.
6. Julayanont P, Karukote A, Ruthirago D, et al. Idiopathic intracranial hypertension: ongoing clinical challenges and future prospects. *J Pain Res*. 2016;9:87-99.
7. Friedman DI, Digre KB. Headache medicine meets neuro-ophthalmology: exam techniques and challenging cases. *Headache*. 2013;53:703-716.
8. Digre KB, Nakamoto BK, Warner JE, et al. A comparison of idiopathic intracranial hypertension with and without papilledema. *Headache*. 2009;49:185-193.
9. Digre KB. Imaging characteristics of IIH: are they reliable? *Cephalalgia*. 2013;33:1067-1069.
10. Horton J. Acetazolamide for pseudotumor cerebri—evidence from the NORDIC trial. *JAMA*. 2014;311:1618-1619.
11. Petrushkin H, Barsam A, Mavrakakis M, et al. Optic disc assessment in the emergency department: a comparative study between the PanOptic and direct ophthalmoscopes. *Emerg Med J*. 2012;29:1007-1008.